Replies to post #113213 on Biotech Values

[DewDiligence]

I still don't get why the Street still don't see TEVA's spin and hammer MNTA every time TEVA come up with BS like that.

You can’t really blame today’s price action on the sell-side analysts (as you could, for instance with the sell-off last August—see #msg-52999229). Although there was a fairly wide divergence of opinion, the overall tenor from the sell-side analysts today was closer to neutral than outright negative, IMO.

[jbog]

Alertmeipp,

In hindight with yesterdays strong gains coupled with this mornings open (pre-market) at $19.77 my guess was that the street saw it as 'bad news' for Teva. It was Teva's spin that changed everything.

Teva's real headline should read ' We haven't been approved yet'.

[jbog]

Alermeipp



“Teva could gain approval for generic Lovenox in the near- term,” Eric Schmidt, an analyst with Cowen & Co. in New York, said today in a note to clients. Teva’s FDA clearance could drive Momenta shares down as low as $8, he said.